| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V36641-1mg |
≥99% | ￥1980.00 |
货期：3-5天 | - | - | - | - |
|
V36641-5mg |
≥99% | ￥4920.00 |
货期：3-5天 | - | - | - | - |
|
V36641-10mg |
≥99% | ￥7130.00 |
货期：3-5天 | - | - | - | - |
|
V36641-25mg |
≥99% | ￥10600.00 |
货期：3-5天 | - | - | - | - |
|
V36641-50mg |
≥99% | ￥13800.00 |
货期：3-5天 | - | - | - | - |
|
V36641-100mg |
≥99% | ￥17500.00 |
货期：3-5天 | - | - | - | - |
|
| 体内研究： | The anti-SRBC PFC response per spleen, which is prominently lowered by restraint-stress (P<0.05), is significantly restored by the administration of TOK-8801 (0.5 mg/kg, P<0.05). The number of total splenic lymphocytes in restraint-stress is decreased, but there are no significant changes in the number of total splenic lymphocytes by the treatment with TOK-8801. When TOK-8801 is administered orally at doses of 0.1 to 10 mg/kg, the number of plaque forming cell (PFC) significantly decreases or tends to decrease. Treatment of TOK-8801 at doses of 0.1 to 1 mg/kg causes significant suppression in the delayed-type hypersensitivity (DTH) reaction induced in high responder. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 参考文献： | 1. Fujiwara M, et al. Immunomodulatory activity of the newly synthesized compound TOK-8801 (N-(2-phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo[2,1-b]thiazole-2- carboxamide). Jpn J Pharmacol. 1989 Dec;51(4):549-54. 2. Shibata K, et al. Immunomodulatory effect of a newly synthesized compound, TOK-8801 (N-(2-phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo [2,1-b]thiazole-2-carboxamide) on antibody production in vivo and delayed-type hypersensitivity in mice. Int J Immunopharmacol. 1990;12(5):497-502. |
||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京